NCT02978339View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

November 16, 2018

Study Completion Date

January 8, 2019

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Curcumin

Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.

Trial Locations (1)

55905-0001

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

EuroPharma, Inc.

INDUSTRY

lead

John E. Eaton

OTHER

NCT02978339 - A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC) | Biotech Hunter | Biotech Hunter